Hello all, Below is what Joanne Katz sent me la
Post# of 30066
Posted On: 03/22/2015 8:58:29 AM
Hello all,
Below is what Joanne Katz sent me late last night. That is why I posted it. I thought it was the actual presentation.
"It was already on Friday:
A. Beta-Amyloid Diseases
06r. Imaging & Biomarkers: other
Date: Friday 20th - Posters
PARKINSON’S DISEASE BIOMARKER DISCOVERY USING SOMASCAN PROTEOMIC TECHNOLOGY
155
J. Ash, United Kingdom
IDENTIFICATION OF SYNAPTIC PROTEINS DETECTABLE IN THE CEREBROSPINAL FLUID IN THE SEARCH FOR BIOMARKERS OF PRECLINICAL ALZHEIMER'S DISEASE
156
O. Belbin, Spain
DEVELOPMENT OF NEW MASS SPECTROMETRY BASED ASSAYS FOR ANALYSIS OF HUMAN CEREBROSPINAL FLUID
157
G. Brinkmalm, Sweden
RATIONAL DESIGN OF ENVIRONMENT SENSITIVE FLUOROPHORES FOR DETECTION OF AGGREGATED AMYOID PROTEIN BIOMARKERS IN NEUROLOGICAL DISEASES
158
K. Cao, USA
BINDING IN VISUAL WORKING MEMORY: A COGNITIVE BIOMARKER FOR EARLY ALZHEIMER'S DISEASE?
160
M. Heider, Germany
SEARCHING FOR A MOLECULAR SIGNATURE OF ALZHEIMER'S DISEASE IN DOWN SYNDROME PLASMA
161
M.F. Iulita, Canada
PLASMA CHOLINE ACETYLTRANSFERASE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND AD
162
A. Karami, Sweden
THE LYMPRO® ASSAY: A BIOMARKER FOR ALZHEIMER’S DISEASE USING BLOOD SAMPLES FROM CLINICALLY DIAGNOSED ALZHEIMER’S DISEASE AND COGNITIVELY INTACT SUBJECTS
163
L. Kirby, USA
PLASMA AND CSF PROTEINS JOINTLY PREDICT MID-TERM PROGRESSION FROM MCI TO AD
164
B. Lehallier, USA
PREPARATION AND STABILITY TESTING OF A QUALITY CONTROL MATERIAL FOR NEUROCHEMICAL DEMENTIA DIAGNOSTICS ASSAYS
165
P. Lewczuk, Germany
AMYLOID BETA 42/40 CSF CONCENTRATION RATIO WITH TWO NOVEL ASSAYS FOR AN EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE
166
P. Lewczuk, Germany
CYP2D6 GENE AND PLASMA CONCENTRATION OF S-DONEPEZIL AS BIOMARKERS TO PREDICT AND EVALUATE CLINICAL OUTCOME OF DONEPEZIL IN CHINESE ALZHEIMER’S DISEASE PATIENTS
167
J. Lu, China
DECREASED LEVELS OF CGMP IN CSF ARE ASSOCIATED WITH COGNITIVE DECLINE AND AMYLOID PATHOLOGY IN ALZHEIMER’S DISEASE
168
C. Mar, Spain
HIPPOCAMPAL SUBFIELDS REPRODUCIBILITY: A EUROPEAN MULTI-SITE 3T STUDY
169
M. Marizzoni, Italy
A NOVEL IMMUNOASSAY FOR LONGITUDINAL MEASUREMENTS OF AMYLOID-BETA OLIGOMERS IN HUMAN CSF WITH POTENTIAL TO ASSESS THERAPEUTIC RESPONSE TO IMMUNOTHERAPY
170
M. Matijevic, USA
AUTOMATION OF COMMERCIAL AMYLOID-BETA AND TAU ELISAS WILL LOWER INTER-LAB VARIABILITY
171
A. Matzen, Germany
CSF BIOMARKER VARIABILITY IN THE ALZHEIMER´S ASSOCIATION QUALITY CONTROL PROGRAM
172
S. Persson, Sweden
EVALUATION OF RETINAL CHANGES IN MILD COGNITIVE IMPAIRMENT, ALZHEIMER DEMENTIA, NON-ALZHEIMER DEMENTIA AND PD
173
J. Pillai, USA
CHANGES OF PLASMA AMYLOID BETA 40/42 RATIOS IN KOREAN SPORADIC EARLY-ONSET ALZHEIMER'S DISEASE PATIENTS
174
P. Sun Ah, Korea
RED BLOOD CELL FATTY ACIDS ARE SIGNIFICANTLY ALTERED IN SOUTH AUSTRALIAN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE COMPARED TO CONTROLS
175
P. Thomas, Australia
IMPACT OF FREQUENT CSF SAMPLING ON CSF ABETA LEVELS: SYSTEMATIC APPROACH TO ELUCIDATE INFLUENCING FACTORS
176
B. Van Broeck, Belgium
SPEECH DISORDERS IN ALZHEIMER´S DISEASE
177
P. Walecki, Poland
GLYCOSYLATION OF HUMAN PLASMA CLUSTERIN PROVIDES NOVEL BIOMARKERS OF ALZHEIMER’S DISEASE
178
M. Ward, United Kingdom
PLASMA IL-6 AND TRAIL IDENTIFIED AS BIOMARKERS OF ALZHEIMER'S DISEASE
179
Y. Wu, Taiwan
Kind regards,
Joanne Katz
Project Coordinator
kenes-international
Tel: +41 22 9080488 Ext 920
Fax: +41 22 9069140
Email: jkatz@kenes.com
Site: www.kenes.com "
Manolo
Below is what Joanne Katz sent me late last night. That is why I posted it. I thought it was the actual presentation.
"It was already on Friday:
A. Beta-Amyloid Diseases
06r. Imaging & Biomarkers: other
Date: Friday 20th - Posters
PARKINSON’S DISEASE BIOMARKER DISCOVERY USING SOMASCAN PROTEOMIC TECHNOLOGY
155
J. Ash, United Kingdom
IDENTIFICATION OF SYNAPTIC PROTEINS DETECTABLE IN THE CEREBROSPINAL FLUID IN THE SEARCH FOR BIOMARKERS OF PRECLINICAL ALZHEIMER'S DISEASE
156
O. Belbin, Spain
DEVELOPMENT OF NEW MASS SPECTROMETRY BASED ASSAYS FOR ANALYSIS OF HUMAN CEREBROSPINAL FLUID
157
G. Brinkmalm, Sweden
RATIONAL DESIGN OF ENVIRONMENT SENSITIVE FLUOROPHORES FOR DETECTION OF AGGREGATED AMYOID PROTEIN BIOMARKERS IN NEUROLOGICAL DISEASES
158
K. Cao, USA
BINDING IN VISUAL WORKING MEMORY: A COGNITIVE BIOMARKER FOR EARLY ALZHEIMER'S DISEASE?
160
M. Heider, Germany
SEARCHING FOR A MOLECULAR SIGNATURE OF ALZHEIMER'S DISEASE IN DOWN SYNDROME PLASMA
161
M.F. Iulita, Canada
PLASMA CHOLINE ACETYLTRANSFERASE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND AD
162
A. Karami, Sweden
THE LYMPRO® ASSAY: A BIOMARKER FOR ALZHEIMER’S DISEASE USING BLOOD SAMPLES FROM CLINICALLY DIAGNOSED ALZHEIMER’S DISEASE AND COGNITIVELY INTACT SUBJECTS
163
L. Kirby, USA
PLASMA AND CSF PROTEINS JOINTLY PREDICT MID-TERM PROGRESSION FROM MCI TO AD
164
B. Lehallier, USA
PREPARATION AND STABILITY TESTING OF A QUALITY CONTROL MATERIAL FOR NEUROCHEMICAL DEMENTIA DIAGNOSTICS ASSAYS
165
P. Lewczuk, Germany
AMYLOID BETA 42/40 CSF CONCENTRATION RATIO WITH TWO NOVEL ASSAYS FOR AN EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE
166
P. Lewczuk, Germany
CYP2D6 GENE AND PLASMA CONCENTRATION OF S-DONEPEZIL AS BIOMARKERS TO PREDICT AND EVALUATE CLINICAL OUTCOME OF DONEPEZIL IN CHINESE ALZHEIMER’S DISEASE PATIENTS
167
J. Lu, China
DECREASED LEVELS OF CGMP IN CSF ARE ASSOCIATED WITH COGNITIVE DECLINE AND AMYLOID PATHOLOGY IN ALZHEIMER’S DISEASE
168
C. Mar, Spain
HIPPOCAMPAL SUBFIELDS REPRODUCIBILITY: A EUROPEAN MULTI-SITE 3T STUDY
169
M. Marizzoni, Italy
A NOVEL IMMUNOASSAY FOR LONGITUDINAL MEASUREMENTS OF AMYLOID-BETA OLIGOMERS IN HUMAN CSF WITH POTENTIAL TO ASSESS THERAPEUTIC RESPONSE TO IMMUNOTHERAPY
170
M. Matijevic, USA
AUTOMATION OF COMMERCIAL AMYLOID-BETA AND TAU ELISAS WILL LOWER INTER-LAB VARIABILITY
171
A. Matzen, Germany
CSF BIOMARKER VARIABILITY IN THE ALZHEIMER´S ASSOCIATION QUALITY CONTROL PROGRAM
172
S. Persson, Sweden
EVALUATION OF RETINAL CHANGES IN MILD COGNITIVE IMPAIRMENT, ALZHEIMER DEMENTIA, NON-ALZHEIMER DEMENTIA AND PD
173
J. Pillai, USA
CHANGES OF PLASMA AMYLOID BETA 40/42 RATIOS IN KOREAN SPORADIC EARLY-ONSET ALZHEIMER'S DISEASE PATIENTS
174
P. Sun Ah, Korea
RED BLOOD CELL FATTY ACIDS ARE SIGNIFICANTLY ALTERED IN SOUTH AUSTRALIAN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE COMPARED TO CONTROLS
175
P. Thomas, Australia
IMPACT OF FREQUENT CSF SAMPLING ON CSF ABETA LEVELS: SYSTEMATIC APPROACH TO ELUCIDATE INFLUENCING FACTORS
176
B. Van Broeck, Belgium
SPEECH DISORDERS IN ALZHEIMER´S DISEASE
177
P. Walecki, Poland
GLYCOSYLATION OF HUMAN PLASMA CLUSTERIN PROVIDES NOVEL BIOMARKERS OF ALZHEIMER’S DISEASE
178
M. Ward, United Kingdom
PLASMA IL-6 AND TRAIL IDENTIFIED AS BIOMARKERS OF ALZHEIMER'S DISEASE
179
Y. Wu, Taiwan
Kind regards,
Joanne Katz
Project Coordinator
kenes-international
Tel: +41 22 9080488 Ext 920
Fax: +41 22 9069140
Email: jkatz@kenes.com
Site: www.kenes.com "
Manolo
(0)
(0)